Celyad Oncology (CYAD)

Company Profile

Celyad Oncology is a biotechnology company focused on the discovery and development of innovative technologies chimeric antigen receptor (CAR) T-cell therapies. The Company is focusing on opportunities to fully harness the true potential of its proprietary technology platforms and intellectual property and support the development of next-generation CAR T candidates in solid tumors and hematological malignancies. Celyad Oncology is based in Mont-Saint-Guibert, Belgium and New York, NY. For more information, please visit www.celyad.com.

Company profile

Ticker

CYAD

Exchange

NASDAQ

Website

www.celyad.com/

CEO

Filippo Petti

Incorporated

Belgium

Location

Belgium

Fiscal year end

Dec 31

Sector

Manufacturing > Pharmaceutical Preparation Manufacturing

Industry (SIC)

Pharmaceutical Preparations

Pfizer • Johnson & Johnson • Merck & Co • Abbott Laboratories • Teva- Pharmaceutical Industries • Bristol-Myers Squibb • Lilly(Eli) & Co • Viatris • Abbvie • Celgene ...

Former names

CARDIO3 BIOSCIENCES S.A., CELYAD S.A.

SEC CIK

0001637890

Corporate docs

Articles of Incorporation & Bylaws

Underwriting Agreements

Plans of Reorganization

Indentures

Material Contracts & Credit Agreements

Subsidiaries Lists

CYAD stock data

1M 1Y 5Y

Latest filings (excl ownership)

View all

6-K

Celyad Oncology provides fourth quarter 2022 business update and 2023 outlook

3 Feb 23

6-K

Current report (foreign)

21 Dec 22

6-K

Celyad Oncology Announces Third Quarter 2022 Financial Results and Recent Business Highlights

10 Nov 22

6-K

Celyad Oncology Provides Strategic Update

12 Oct 22

6-K

Cellistic and Celyad Oncology Announce GMP Cell Therapy Manufacturing Operations Transaction

20 Sep 22

6-K

Celyad Oncology Reports First Half 2022 Financial Results and Recent Business Highlights

5 Aug 22

6-K

Celyad Oncology Announces FDA Lifts Clinical Hold of CYAD-101-002 Phase 1b Trial

1 Aug 22

6-K

Celyad Oncology Announces Leadership Updates

24 Jun 22

6-K

Celyad Oncology Announces First Quarter 2022 Financial Results and Recent Business Highlights

6 May 22

6-K

Celyad Oncology Reports Full Year 2021 Financial Results and Recent Business Highlights

24 Mar 22

Transcripts

CYAD

Earnings call transcript

2022 Q2

5 Aug 22

CYAD

Earnings call transcript

2021 Q4

25 Mar 22

CYAD

Earnings call transcript

2021 Q2

7 Aug 21

Latest ownership filings

SC 13D

Fortress Investment Group LLC

17 Dec 21

SC 13G/A

VICTORY CAPITAL MANAGEMENT INC

2 Feb 21

SC 13G/A

Beneficial ownership report (amended)

Financial summary

Financial statements Chart CYAD financial data

Quarter (USD)	Dec 21	Dec 20	Dec 19	Dec 18
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 21	Dec 20	Dec 19	Dec 18
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from company earnings reports.

Institutional ownership, Q3 2022

CYAD institutional ownership history Ownership history

29.1% owned by funds/institutions

13F holders	Current	Prev Q	Change
Total holders	8	8	–
Opened positions	2	1	+100.0%
Closed positions	2	1	+100.0%
Increased positions	1	0	NEW
Reduced positions	2	4	-50.0%

13F shares	Current	Prev Q	Change
Total value	9.07 mm	11.38 mm	-20.3%
Total shares	6.57 mm	6.58 mm	-0.0%
Total puts	0.00	0.00
Total calls	0.00	0.00
Total put/call ratio	–	–	–

Largest owners	Shares	Value	Change
FIG Fortress Investment	6.50 mm	$8.97 mm	0.0%
MS Morgan Stanley	18.90 k	$26.00 k	-5.0%
Citadel Advisors	16.65 k	$22.00 k	NEW
WFC Wells Fargo & Co.	12.87 k	$18.00 k	-7.2%
Susquehanna International	11.60 k	$16.00 k	NEW
UBS UBS Group AG - Registered Shares	8.71 k	$12.00 k	+115.1%
National Bank of Canada	3.40 k	$5.00 k	0.0%
Advisor	1.50 k	$2.00 k	0.0%

Largest transactions	Shares	Bought/sold	Change
HRT Financial	0.00	-33.29 k	EXIT
Citadel Advisors	16.65 k	+16.65 k	NEW
Susquehanna International	11.60 k	+11.60 k	NEW
UBS UBS Group AG - Registered Shares	8.71 k	+4.66 k	+115.1%
WFC Wells Fargo & Co.	12.87 k	-1.00 k	-7.2%
MS Morgan Stanley	18.90 k	-1.00 k	-5.0%
Credit Suisse	0.00	-838.00	EXIT
National Bank of Canada	3.40 k	0.00	0.0%
FIG Fortress Investment	6.50 mm	0.00	0.0%
Advisor	1.50 k	0.00	0.0%

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.